UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 127

Sortiert nach

Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability

Annals of oncology, 2018-10, Vol.29, p.viii297-viii297

2018

Volltextzugriff (PDF)

Plasmapheresis in the treatment of hypertriglyceridemia‐induced pancreatitis: A community hospital's experience

Journal of clinical apheresis, 2010, Vol.25 (4), p.229-234

2010

Volltextzugriff (PDF)

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date

Cancer management and research, 2020-01, Vol.12, p.7321-7330

2020

Volltextzugriff (PDF)

The effect of high-calorie meal consumption on oxidative stress and endothelial dysfunction in healthy male adults

Physiological research, 2013-01, Vol.62 (6), p.643-652

2013

Volltextzugriff (PDF)

Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

International journal of radiation oncology, biology, physics, 2022-11, Vol.114 (3), p.e243-e244

2022

Volltextzugriff (PDF)

1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2022-09, Vol.33, p.S1191

2022

Volltextzugriff (PDF)

957O Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1

Annals of oncology, 2021-09, Vol.32, p.S829-S829

2021

Volltextzugriff (PDF)

605P Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide

Annals of oncology, 2021-09, Vol.32, p.S647-S647

2021

Volltextzugriff (PDF)

681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc)

Annals of oncology, 2020-09, Vol.31, p.S542-S542

2020

Volltextzugriff (PDF)

616MO Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Results from a preliminary analysis of the Quick Efficacy Seeking Trial (QuEST1)

Annals of oncology, 2020-09, Vol.31, p.S511-S511

2020

Volltextzugriff (PDF)

643P Evaluating biomarkers in metastatic castration resistant prostate cancer (mCRPC) patients (Pts) treated with enzalutamide (Enza): PSA, circulating tumor cell (CTC) counts, AR-V7 status, PET imaging vs. CT & Tc99 scans

Annals of oncology, 2020-09, Vol.31, p.S527-S528

2020

Volltextzugriff (PDF)

A phase I study of Ad5 PSA/MUC-1/brachyury vaccine in patients with metastatic castration resistant prostate cancer (mCRPC)

Annals of oncology, 2019-10, Vol.30, p.v342-v343

2019

Volltextzugriff (PDF)

874P - A phase I study of Ad5 PSA/MUC-1/brachyury vaccine in patients with metastatic castration resistant prostate cancer (mCRPC)

Annals of oncology, 2019-10, Vol.30, p.v342-v343

2019

Volltextzugriff (PDF)

Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy

European journal of cancer (1990), 2020-10, Vol.138, p.S10-S10

2020

Volltextzugriff (PDF)

SO-28 A randomized phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer

Annals of oncology, 2020-07, Vol.31, p.S227

2020

Volltextzugriff (PDF)

Inadequate use of preventive strategies in patients receiving NSAIDs

Clinical drug investigation, 2005, Vol.25 (4), p.265-270

2005

Volltextzugriff (PDF)

A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC)

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.163-163

2011

Volltextzugriff (PDF)

Mapping the Genetic Determinants of Hypertension, Metabolic Diseases, and Related Phenotypes in the Lyon Hypertensive Rat

Hypertension (Dallas, Tex. 1979), 2004-11, Vol.44 (5), p.695-701

2004

Volltextzugriff (PDF)

Abstract P5-16-06: A phase 2 randomized trial of docetaxel (DOC) alone or in combination with therapeutic cancer vaccine, CEA-, MUC-1-TRICOM (PANVAC)

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P5-P5-16-06

2012

Volltextzugriff (PDF)

Recurrent Bulbar Paralysis Caused by Botulinum Toxin Type B

Clinical infectious diseases, 2008-04, Vol.46 (8), p.e72-e74

2008

Volltextzugriff (PDF)

A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.2604-2604

2011

Volltextzugriff (PDF)

Autoimmune Disorders During Interferon Therapy in a Patient With Chronic Hepatitis C Infection: How Many of Them Can Be Observed in a Single Patient?

Journal of clinical gastroenterology, 2006-04, Vol.40 (4), p.367-368

2006

Volltextzugriff (PDF)

874PA phase I study of Ad5 PSA/MUC-1/brachyury vaccine in patients with metastatic castration resistant prostate cancer (mCRPC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

850PIntermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Acquired coagulopathy due to anticoagulant rodenticide poisoning

Croatian medical journal, 2002-10, Vol.43 (5), p.615

2002

Volltextzugriff (PDF)

1 – 25 von 127

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(113)
Mit Volltextzugriff
(118)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(43)
Humans
(25)
Oncology
(25)
Male
(21)
Immunotherapy
(13)
Physical Sciences
(12)
Physics
(11)
Aged
(10)
Female
(10)
Middle Aged
(10)
Prostate Cancer
(10)
Urology & Nephrology
(9)
Immunology
(8)
Treatment Outcome
(8)
Metastasis
(7)
Physics, Condensed Matter
(7)
Adult
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(6)
Exact Sciences And Technology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability

Plasmapheresis in the treatment of hypertriglyceridemia‐induced pancreatitis: A community hospital's experience

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date

The effect of high-calorie meal consumption on oxidative stress and endothelial dysfunction in healthy male adults

Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC)

957O Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1

605P Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide

681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc)

616MO Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Results from a preliminary analysis of the Quick Efficacy Seeking Trial (QuEST1)

643P Evaluating biomarkers in metastatic castration resistant prostate cancer (mCRPC) patients (Pts) treated with enzalutamide (Enza): PSA, circulating tumor cell (CTC) counts, AR-V7 status, PET imaging vs. CT & Tc99 scans

A phase I study of Ad5 PSA/MUC-1/brachyury vaccine in patients with metastatic castration resistant prostate cancer (mCRPC)

874P - A phase I study of Ad5 PSA/MUC-1/brachyury vaccine in patients with metastatic castration resistant prostate cancer (mCRPC)

Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy

SO-28 A randomized phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer

Inadequate use of preventive strategies in patients receiving NSAIDs

A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC)

Mapping the Genetic Determinants of Hypertension, Metabolic Diseases, and Related Phenotypes in the Lyon Hypertensive Rat

Abstract P5-16-06: A phase 2 randomized trial of docetaxel (DOC) alone or in combination with therapeutic cancer vaccine, CEA-, MUC-1-TRICOM (PANVAC)

Recurrent Bulbar Paralysis Caused by Botulinum Toxin Type B

A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA

Autoimmune Disorders During Interferon Therapy in a Patient With Chronic Hepatitis C Infection: How Many of Them Can Be Observed in a Single Patient?

874PA phase I study of Ad5 PSA/MUC-1/brachyury vaccine in patients with metastatic castration resistant prostate cancer (mCRPC)

850PIntermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability

Acquired coagulopathy due to anticoagulant rodenticide poisoning

Suchergebnisse filtern